Trial Profile
Pulmonary NTM disease: A regimen of ethambutol and azithromycin with as adjunctive rifampicin vs clofazimine.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2020
Price :
$35
*
At a glance
- Drugs Azithromycin (Primary) ; Clofazimine (Primary) ; Ethambutol (Primary) ; Rifampicin
- Indications Mycobacterium avium complex infections
- Focus Therapeutic Use
- 01 Dec 2020 Status changed from recruiting to discontinued.
- 09 Mar 2016 New trial record